Poster Session E - Tuesday Afternoon
Category: IBD
Anita Afzali, MD, MPH, FACG
The Ohio State University Wexner Medical Center
Columbus, Ohio
Table. Clinical Endpoints at Week 12 in Bio-Exposed Patients
Endpoint | Deucravacitinib 6 mg BID (n = 31) | Placebo (n = 16) |
Clinical remission response rate, mean | 16.1% | 0.0% |
Clinical response rate, mean | 29.0% | 12.5% |
Endoscopic improvement response rate, mean | 25.8% | 12.5% |
Symptomatic Mayo score, mean change from baseline (a) | -2.1% | -0.1 |